Saturday 17 October 2026
Export SRTS’s income statement to Excel — free account
Sensus Healthcare, Inc.
SRTS Healthcare Medical Devices
Sensus Healthcare, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $27.5 million, down 34.3% from fiscal 2024. In the quarter to June 2026, revenue fell 68.7%, EPS fell 783.3% and free cash flow fell 201.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.77
0.00
0.00%
Follow SRTS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.44 | 2.36 | 2.91 | 2.84 | |
P/FCF ratio |
23.65 | 195.73 | 0.00 | 0.00 | |
P/Operating CF |
22.33 | (29.44) | (17.46) | (15.87) | |
P/B ratio |
1.00 | 1.35 | 1.44 | 1.35 | |
Price to Tangible BV |
1.00 | 1.35 | 1.44 | 1.35 | |
EV/Sales |
0.92 | 1.77 | 2.35 | 2.31 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
17.10 | 92.31 | (96.78) | (5.94) | |
EV/FCF |
15.06 | 146.81 | (71.67) | (5.79) | |
Quick Ratio |
4.97 | 5.96 | 3.74 | 3.90 | |
Current Ratio |
7.38 | 9.72 | 7.27 | 8.71 | |
Net Debt/EBITDA |
10.15 | 7.40 | 4.36 | 5.01 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.60 | 0.48 | 0.40 | 0.35 | |
Operating CF/Net income |
(2.43) | 0.70 | 1.43 | 0.36 | |
Capex/Depreciation |
(0.03) | (0.96) | (0.02) | (0.05) | |
Research and Development Expense of Revenue |
26.42% | 38.10% | 46.85% | 48.43% | |
Selling, General and Administrative Expense of Revenue |
50.31% | 64.06% | 110.75% | 124.02% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
1.06% | 1.54% | 2.06% | 3.06% | |
Graham Net Nets |
0.84 | 0.63 | 0.56 | 0.67 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(6.05%) | (11.81%) | (11.81%) | (31.13%) | |
Free Cash Flow Yield |
4.23% | 0.51% | (1.13%) | (14.02%) | |
Revenue per Share |
0.42 | 0.30 | 0.21 | 0.14 | |
Operating CF per Share |
0.14 | (0.14) | (0.23) | (0.19) | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.14 | (0.14) | (0.23) | (0.19) | |
Cash per Share |
1.50 | 1.35 | 1.11 | 0.92 | |
Shareholders Equity per Share |
3.14 | 2.95 | 2.77 | 2.24 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.14 | 2.95 | 2.77 | 2.24 | |
Free Cash Flow |
2.29 | (2.36) | (3.76) | (3.14) | |
Working Capital |
43.40 | 41.17 | 36.73 | 33.35 | |
Capital Expenditures |
0.00 | (0.16) | 0.00 | (0.01) | |
Net Current Asset Value |
43.10 | 40.95 | 36.59 | 33.28 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.03 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
13.15 | 12.89 | 10.80 | 7.15 | |
Average Payables |
4.80 | 4.08 | 5.16 | 4.27 | |
Average Inventory |
14.04 | 14.76 | 17.28 | 17.08 | |
Average Assets |
59.08 | 57.60 | 55.88 | 50.06 | |
Average Common Equity |
52.66 | 51.96 | 49.29 | 44.46 |
Columns are period end dates